Benzinga · Aug 25, 2026
TD Cowen Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $10
TD Cowen analyst Nicholas Lorusso maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $7 to $10.
IO
NASDAQ · IOVA
Iovance Biotherapeutics, Inc.
Healthcare · Biotechnology
$8.26
Down-$0.10 (-1.21%)
Updated Aug 28, 2026, 2:03 PM
SID Score
6.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 744.64M
- P/E ratio
- -1.93
- Dividend yield
- 0.00%
- 52-week range
- $1.76 – $9.36
- Volume
- 7.44M
- Avg. volume
- 13.69M
Price performance
IOVA price history
1M range · 21 trading sessions · Daily adjusted prices
IOVA closed at $8.26 after 21 trading sessions, up 76.12% for the selected period.
- Last close
- $8.26
- Period change
- +76.12%
- Period low
- $4.07
- Period high
- $8.99
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $8.08 | $8.3186 | $7.95 | $8.26 | 7.44M |
| Aug 26, 2026 | $8.34 | $8.55 | $8.02 | $8.08 | 10.1M |
| Aug 25, 2026 | $8.16 | $8.48 | $8.0307 | $8.44 | 11.91M |
| Aug 24, 2026 | $8.08 | $8.36 | $7.79 | $8.06 | 15.73M |
| Aug 21, 2026 | $9.08 | $9.30 | $8.145 | $8.29 | 27.81M |
| Aug 20, 2026 | $8.07 | $9.36 | $7.96 | $8.99 | 43.81M |
| Aug 19, 2026 | $7.20 | $8.055 | $7.19 | $7.99 | 24.25M |
| Aug 18, 2026 | $7.00 | $7.31 | $6.931 | $7.03 | 10.5M |
| Aug 17, 2026 | $6.84 | $7.2499 | $6.7031 | $7.10 | 14.81M |
| Aug 14, 2026 | $6.52 | $7.00 | $6.36 | $6.98 | 17.51M |
| Aug 13, 2026 | $6.74 | $6.81 | $6.424 | $6.52 | 15.68M |
| Aug 12, 2026 | $6.49 | $6.74 | $6.39 | $6.74 | 13.46M |
| Aug 11, 2026 | $6.48 | $6.525 | $6.18 | $6.49 | 10.38M |
| Aug 10, 2026 | $6.31 | $6.61 | $6.16 | $6.40 | 17.31M |
| Aug 7, 2026 | $6.57 | $6.92 | $5.88 | $6.34 | 30.97M |
| Aug 6, 2026 | $5.95 | $6.39 | $5.63 | $6.21 | 73.43M |
| Aug 5, 2026 | $4.45 | $4.55 | $4.29 | $4.34 | 15.6M |
| Aug 4, 2026 | $4.39 | $4.48 | $4.29 | $4.36 | 10.68M |
| Aug 3, 2026 | $4.10 | $4.36 | $3.96 | $4.315 | 13.02M |
| Jul 31, 2026 | $4.43 | $4.55 | $4.02 | $4.07 | 19.97M |
| Jul 30, 2026 | $4.53 | $4.8399 | $4.51 | $4.69 | 14.16M |
Latest IOVA news
The latest Smart Investors Daily articles mentioning IOVA.
Stock researchCompany · Overview
IOVA research
Overview
Company profile and research snapshot.
Company profile
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 20, 2026 | UBS | Neutral | — |
| Aug 18, 2026 | Mizuho | Outperform | — |
| Aug 7, 2026 | Citizens | Market Outperform | — |
| Aug 7, 2026 | Barclays | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 21, 2026
Iovance Biotherapeutics Stock Is Trending Friday: What's Going On?
Shares of Iovance Biotherapeutics are trending Friday morning after a momentum surge pushed the biotech stock to a new 52-week high.
Benzinga · Aug 20, 2026
Why Iovance Biotherapeutics Stock Hit 52-Week High
Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amtagvi sales and analyst price target hikes.
Benzinga · Aug 20, 2026
UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $7
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $4 to $7.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
